Experts to Present Live Online Seminar on Galectin-3 at European Society of Cardiology
Respected MDs from University of Michigan, Oslo University, University Medical Center Groningen, and BG Medicine to Present Live Online August 30 at 12:00 PM EDT at www.CardioCareLive.com
Boston, MA August 16, 2011 – Cardiologists from around the world will have an opportunity to learn more about the role of galectin-3 in cardiac disease live via video at no cost at CardioCareLive, the premier online cardiology congress destination. BG Medicine, Inc. (NASDAQ:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, will be will hosting the interactive medical education program titled, “Role of Galectin-3 in Therapeutic and Cardiovascular Outcomes – Results from Leading Studies Presented at the European Society of Cardiology Annual Meeting” on Tuesday, August 30, 2011, at 12:00 PM EDT.
The faculty will feature Bertram Pitt, MD, FACC, Professor of Medicine Emeritus, University of Michigan School of Medicine, Division of Cardiology; Lars Gullestad, MD, PhD, Department of Cardiology, Oslo University Hospital Rikshospitalet; and Rudolf De Boer, MD, PhD, Associate Professor in Cardiology, University Medical Center Groningen. Pieter Muntendam, MD, President and CEO of BG Medicine will moderate the session. Dr. Pitt’s research covers many areas of cardiovascular disease, with special emphasis on ischemic heart disease and heart failure. Dr. Gullestad is an expert in the role of inflammatory and immunological factors in cardiovascular disease and Dr. Boer’s research interests include regulation of the renin-angiotensin system, specifically renin regulation, in experimental and clinical heart failure. Dr. Muntendam is President and CEO of BG Medicine. This program is sponsored by Abbott, Alere, Inc., bioMérieux and Siemens.
For time-constrained cardiologists and other healthcare practitioners, CardioCareLive offers an effective way to stay current on advances in cardiovascular patient care easily online. There is no cost to register and watch any educational session at CardioCareLive. Practitioners who attend live may take advantage of interactive capabilities by texting in questions to be addressed live online by presenting faculty. The program will cover these topics on the role of galectin-3 in cardiac disease:
- Overview of cardiac fibrosis and heart failure
- Galectin-3 predicts mortality and response to statin therapy in chronic heart failure – the role of galectin-3 in predicting response to therapy in heart failure for select drug classes
- Galectin-3, cardiovascular risk factors, and outcome in the general population – the ability of galectin-3 to identify people at risk for cardiovascular events prior to first diagnosis of heart failure
- Genetic disruption of galectin-3 prevents adverse cardiac remodeling - the mechanism and role of galectin-3 in heart failure development
- Pharmacological inhibition of galectin-3 attenuates adverse cardiac remodeling and heart failure – blocking galectin-3 using natural carbohydrate compounds and their effect on heart failure redevelopment
To learn more and register at no cost for this live interactive video webcast, visit www.CardioCareLive.com.
ABOUT CARDIOCARELIVE
CardioCareLive, the world’s largest cardiology congress, is produced by PlatformQ and takes place entirely online. CardioCareLive enables cardiologists, internal medicine specialists, family care physicians and other healthcare practitioners interested in understanding and managing patients with cardiovascular disease to learn, connect and interact in real time. CardioCareLive offers virtual medical education at no cost and delivers all the benefits of a physical conference, with live keynote presentations, lectures, real-time interactive Q&A and an exhibit floor, all from the convenience of a computer.
CardioCareLive and PlatformQ are trademarks of PlatformQ, LLC. All other trademarks or service marks are property of their respective owners.
About BG Medicine, Inc.
BG Medicine, Inc. (Nasdaq: BGMD) is a life sciences company focused on the discovery, development, and commercialization of novel, biomarker-based diagnostics to improve patient outcomes and contain healthcare costs. The Company recently launched the BGM Galectin-3TM test for use in patients with heart failure, the first novel blood test for cardiac disease cleared by the U.S. F.D.A. in five years. BG Medicine also has products in development to aid in the diagnosis and management of acute atherothrombosis and lipid disorders. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.
Press@CardioCareLive.com
617.938.6008
Conferences and events that once met in hotels and convention centers now meet live online. Why? Because live online events provide global reach, convenient online access to live video content featuring key opinion leaders, real-time networking with presenters and peers, and the efficient use of time and resources for attendees and supporters.
PlatformQ is the leading producer of live online events for audiences from 500 to 50,000. PlatformQ brings attendees, thought leaders, and product and service providers together in engaging interactive environments. PlatformQ provide marketers with measurable, targeted, and contextual environments for audience education and engagement. The result: more qualified leads, in less time, at lower cost. To learn more, visit www.PlatformQ.com.
Tags: